Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKesson
Mallinckrodt
McKinsey
Chubb
Julphar
Daiichi Sankyo
US Army
Covington
Merck

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,227,484

« Back to Dashboard

Which drugs does patent 8,227,484 protect, and when does it expire?

Patent 8,227,484 protects NUEDEXTA and is included in one NDA.

This patent has fifty-five patent family members in twenty-one countries.
Summary for Patent: 8,227,484
Title:Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Abstract: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Inventor(s): Yakatan; Gerald (Del Mar, CA), Berg; James (San Diego, CA), Pope; Laura (Carlsbad, CA), Smith; Richard Alan (La Jolla, CA)
Assignee: Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA)
Application Number:13/415,067
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,227,484

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Avanir Pharms NUEDEXTA dextromethorphan hydrobromide; quinidine sulfate CAPSULE;ORAL 021879-001 Oct 29, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PSEUDOBULBAR AFFECT ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,227,484

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,282 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,227,484

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200403997 ➤ Subscribe
Slovenia 1980252 ➤ Subscribe
Slovenia 1539166 ➤ Subscribe
Russian Federation 2341265 ➤ Subscribe
Russian Federation 2005104418 ➤ Subscribe
Portugal 1980252 ➤ Subscribe
Portugal 1539166 ➤ Subscribe
Poland 398445 ➤ Subscribe
Poland 213552 ➤ Subscribe
Poland 374026 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Cantor Fitzgerald
Fuji
Teva
UBS
McKinsey
Argus Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot